A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Navacaprant (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms KOASTAL-3
- Sponsors Neumora Therapeutics
Most Recent Events
- 12 May 2025 According to Neumora Therapeutics media release, company anticipates reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026.
- 27 Mar 2025 Planned End Date changed from 1 Jun 2025 to 1 Mar 2026.
- 27 Mar 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Feb 2026.